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Colorectal cancer (CRC) is one of the most common cancers in the western world and is characterised by deregulation of the Wnt
signalling pathway. Mutation of the adenomatous polyposis coli (APC) tumour suppressor gene, which encodes a protein that
negatively regulates this pathway, occurs in almost 80% of CRC cases. The progression of this cancer from an early adenoma to
carcinoma is accompanied by a well-characterised set of mutations including KRAS, SMAD4 and TP53. Using elegant genetic
models the current paradigm is that the intestinal stem cell is the origin of CRC. However, human histology and recent studies,
showing marked plasticity within the intestinal epithelium, may point to other cells of origin. Here we will review these latest
studies and place these in context to provide an up-to-date view of the cell of origin of CRC.
We first need to briefly introduce normal intestinal homeostasis
and stem cells (for a recent in depth review see Vermeulen and
Snippert, 2014).The intestinal epithelium has a remarkable capacity
for self-renewal; every 4–5 days, the majority of the epithelial cells
within the gut are replaced. The intestinal stem cells (ISCs), which
are responsible for the epithelial renewal, reside at the bottom of
the crypt (Figure 1). The immediate daughter cells of the stem cells
proliferate for a finite number of times themselves before fully
differentiating. These transit amplifying (TA) cells are the major
producer of the epithelial cells and are situated directly above the
stem cells (Figure 1A). In an intestinal crypt there are 5–16 ISCs
per crypt and roughly 120–150 TA cells. Only few specialised cells
(e.g., tuft cells, neuroendocrine cells and Paneth cells) live longer
than the average 4–5 days. This rapid turnover of the intestinal
epithelium led to the assumption that the long-lived ISCs are the
most likely cell of origin for tumourigenesis.
PLASTICITY OF STEM CELL IN THE INTESTINE
The ISCs at the bottom of the crypt are defined by high Wnt
activity, a characteristic they share with CRC tumour cells. In
recent years, studies have shown that there is not just a single
defined ISC pool in the intestine, but rather cells in the stem cell
niche that can replace and compensate each other and therefore
can also change their expression profile. There are at least two
functional different ISCs, the crypt base columnar cells (CBCs) and
the slow-proliferating label-retaining cells. With the discovery of
the ISC marker LGR5, it was shown that these CBCs are the main
pool of actively cycling ISCs (Barker et al, 2007).
Other ISC markers with a broader expression at the base of the
crypt have been discovered that label more than the Lgr5þ ve cells,
for example, Lrig1 (Powell et al, 2012), Hoxp1, Bmi1 and mTert
(Montgomery et al, 2011). Although protein expression data have
suggested these to be tightly located (i.e., at position þ 4), RNA
expression data have placed Hoxp1 and Bmi1 relatively broadly at the
base of the crypt (Sangiorgi and Capecchi, 2008; Mun˜oz et al, 2012).
Given that this set of markers are expressed in a wider range of
cells at the base of the crypt helps to explain the studies that show
that LGR5þ ve cells are dispensable for homeostasis of the
intestine. Here LGR5þ ve cells were killed using diphtheria toxin,
but the intestinal homeostasis was unperturbed (Tian et al, 2011).
However, following radiation, the LGR5þ ve cell-depleted intes-
tine was unable to recover (Metcalfe et al, 2014), showing that in
certain circumstances the other cells in the stem cell niche are not
able to compensate this loss.
As expression data have placed many ISC markers rather
broadly at the base of the crypt, a recent study has taken a
functional approach using in vivo imaging to define stem cell
capacity at the base of the crypt. Ritsma et al (2014) showed there
are about 16 LGRþ ve cells in a crypt, some of which are located
towards the centre of the crypt and others which are higher up,
located at the border of the crypt base. Importantly, the probability
of these centre and border stem cells to stay in the crypt over time
and function as a stem cell was different. The ‘central cells’ were
more likely to retain stem cell capacity compared with the ‘border cells’.
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This was not absolute as there is a constant transfer of cells
between these two regions. Therefore the functionality of an ISC is
defined by its position (as has been previously speculated (Sansom
and Na¨thke, 2013)) rather than the expression of a specific protein
marker.
Label-retaining studies using radioactive thymidine precursor
(Potten et al, 1974) and recently by H2B-GFP/-YFP(Roth et al, 2012;
Buczacki et al, 2013) lineage tracing have identified that there are a
set of long-lived cells within the intestine that can act as stem cells as
well and repopulate the intestine post damage. These cells express
secretory markers and can be thought of as early progenitor cells,
which fall back into the stem cell niche following damage and
potentially dedifferentiate to develop full stem cell potential. In a
complementary manner, cells that express Dll1 in the crypt mark
secretory progenitors, which do not normally act as stem cells, but
post damage can repopulate the crypt (Van Es et al, 2012).
Taken together these studies show that the normal intestine has
great plasticity and non-stem cells could dedifferentiate to produce
a stem cell-like phenotype, which is able to repopulate the
intestine. This suggests that there may also be an increased
repertoire of cells that could act as the cell of origin for colorectal
cancer.
INITIATING MUTATIONS IN CRC
In 1990, it was postulated that CRC was caused by the
accumulation of mutations that drive tumour initiation and then
progression (Fearon and Vogelstein, 1990). Indeed, it was
postulated that this process could take over 10 years
(Beerenwinkel et al, 2007). Loss of the APC gene is the likely
initiating mutation followed by additional mutations in KRAS,
TGFB, PI3 Kinase and TP53 signalling pathway components. It is
interesting to note when these mutations are modelled in the
murine intestinal epithelium, apart from Apc loss, the other
mutations alone have very minor impact on intestinal homeostasis
and only yield tumours at very long latencies (Kras, Tp53, Pten).
However, loss of Apc leads to a rapid Wnt deregulation and
acquisition of a crypt-progenitor cell phenotype in the small
intestine and colon (Sansom et al, 2004).
ACQUISITION OF MUTATIONS
How do cells acquire mutations and what are the direct
consequences? It is generally believed that the main source for
mutations in the intestine is due to DNA replication errors and
carcinogenic exposure. Given the high proliferation of the TA cells
and the more restricted zone of proliferation of the ISCs, the TA
cells are more prone to acquire a mutation. However, as long as the
cell migration is not perturbed, these cells would be shed from the
intestine within 3–4 days. Given the relatively mild phenotypes
arising from mutation of most of the major tumour suppressors
and oncogenes, a TA cell with a single mutation would be lost
within a couple of days. The short lifespan of these proliferating
cells reduces the risk of tumour initiation.
An additional mechanism to prevent accumulation of mutated
cells in the crypt is the neutral drift of the ISCs. Until recently it
was believed that ISCs divide by asymmetric cell division, which
means an ISC gives rise to one TA cell and one ISC. Instead, the
ISC division follows a principle of random replacement of ISCs, a
process called ‘neutral drift’ (Lopez-Garcia et al, 2010; Snippert
et al, 2010). This means that a single ISC in a crypt can be replaced
by any of the other ISCs in the crypt. In a scenario with
5 functional ISCs, a marked wild-type stem cell has a 1/5 (20%)
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Figure 1. Methods to induce adenoma formation in stem cells and differentiated cells. (A) Overview of a crypt in the small intestine. The crypt
base columnar (CBC) cells are located at the bottom of the crypt in between the Paneth cells. In addition to the expression of several stem cell
markers, the functionality of the intestinal stem cell (ISC) is determined by its location, with the ‘centre’ ISC having the highest ISC functionality.
(B) The expression of specific stem cell markers has been used to induce cre-driven recombination in ISCs, leading to adenoma formation, either
by loss of Apc or Bcatex3 mutation. Oral administration of low-dose b-naphthoflavone has been used to induce AhCre-dependent Apc loss in cells
above the crypt base, resulting in formation of microadenomas. Recombination in differentiated villus cells only resulted in adenomas when Apc
loss or Bcatex3 mutation was combined with Kras mutation or NFKB activation (villus purification in VilCreER mice or Xbp1sCreER).
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In an elegant study by Vermeulen et al (2013) the consequences
of oncogenic mutations on ISC fitness has been studied. If one ISC
acquires a neutral mutation it has a high risk of being replaced by a
normal stem cell within the crypt. The probability for an Apc
mutation, for example, to become fixed, that is, to populate the
whole crypt is 42% (PR¼ 0.62, N¼ 5 stem cells), which means in
the majority of cases the mutated cell will be replaced by one of its
wild-type stem cell neighbours and will be consequently lost. The
advantage of a Kras mutation (KrasG12D) to populate the whole
crypt is even higher (about 72%), which was confirmed in another
study (Snippert et al, 2014). Although these studies have not taken
into account the different positions of the tracked stem cell at start
of the observation, it demonstrates the mutation itself has a major
impact on the stem cell fitness.
Furthermore it shows that even if a stem cell acquires a
mutation, there is a high chance that the cell will be lost, even if it
has an advantage on the stem cell fitness. This might explain why
CRC takes years to develop, even in patients with a genetic
predisposition (germline APCmut/þ ) to familiar adenomatous
polyposis (FAP) disease.
STEM CELLS AS CELL OF ORIGIN
The discovery of expression markers for ISCs has enabled
functional approaches to be used to test whether they can act
as a cell of origin for intestinal tumourigenesis. Several studies
(see Table 1) have shown that Apc deletion specifically in Lgr5þ
(Barker et al, 2009), Lrigþ (Powell et al, 2012, 2014), CD133/
Prominin1 (Zhu et al, 2009) and other cells can provoke rapid
adenoma formation. Bmi1þ ve cells were also able to form small
intestinal adenomas when an activating b-catenin mutation was
targeted to these cells (Sangiorgi and Capecchi, 2008). Thus it
appears that Wnt activation in the stem cells is sufficient for
adenoma formation in the mouse. One important caveat is that
most of these approaches have been limited to the generation of
intestinal adenomas (most of which form in the small intestine).
NON-STEM CELL ROUTES
In contrast to this plethora of studies showing adenomas
originating from stem cells, there is a more limited literature on
tumours developing via non-stem cells routes in the mouse. This
is in part owing to the rapid turnover of these cells (one would
predict from Cre induction to gene and protein turnover
about 48 h).
Our initial studies to delete Apc in the non-stem cell
compartment using an oral dose of Cre inducer to spare the crypt
stem cells led to the production of a number of small lesions that
were retained within the intestinal epithelium. These however did
not form tumours rapidly and even at 200 days post induction,
many predominantly small lesions remained, though rarely one
would progress to an adenoma. This was the first study to make a
qualitative comparison between stem cells and TA cells as the cell
of origin. Although the Lgr5þ ve cells were much more efficient in
adenoma formation, it is important to note that the mutated TA
cells were not lost and the microscopic lesions found after 280 days
were high in nuclear b-catenin (Barker et al, 2009) (Figure 1B).
Deregulation of Wnt signalling by loss of Apc in Dclk1þ tuft
cells (that do not have stem cell characteristics (Nakanishi et al,
2012)) was not able to induce tumourigenesis. However, when
these APC-deficient tuft cells where challenged with dextran
sulphate sodium to induce colitis, even 3 months after induction,
they formed colonic tumours (Westphalen et al, 2014). This
suggests that Apc loss in a non-stem cell population could initiate
tumourigenesis but would need extra events (e.g., inflammation) to
progress to an adenoma.
These studies suggested that if cells acquire mutations and
persist, additional events (e.g., mutations or inflammation) could
then lead to adenoma progression.
The ability to ‘dedifferentiate’ and the link with pathways
involved in inflammation was tested in more depth by Greten and
colleagues. Activation of the NFKB pathway could provoke crypt-
like structures in the villus and there was strong cooperation of
Wnt pathway and NFKB pathway activation for tumour
initiation. To test whether one of the reasons for increased
tumour initiation was due to an expanded cell of origin
population they used the Xbps1-CreER to target differentiated
cells in the intestine. Xbps1 is an ER stress protein that is not
expressed in stem cells of the intestine and thus allows
recombination in more differentiated cells of the epithelium.
Using this Cre, an activating b-catenin mutation was unable to
transform the intestinal epithelium. However, when a b-catenin
mutation was combined with increased NFKB signalling, tumours
could be formed (Schwitalla et al, 2013).
Importantly, the same study showed that one of the con-
sequences of a KrasG12D mutation in CRC was to activate NFKB
signalling and hence Kras could also initiate tumourigenesis in
differentiated cells when combined with Wnt pathway activation
owing to loss of Apc.
Recently, it was shown that also changes in the intestinal
microenvironment can initiate tumour formation in non-
stem cells (Davis et al, 2014). Hereditary mixed polyposis
syndrome (HMPS) is caused by aberrant expression of the
bone morphogenetic protein (BMP) antagonist ‘GREM1’. This
BMP antagonist is usually expressed by mesenchymal cells, but
owing to a gene duplication, in these patients, it is expressed
by intestinal epithelial cells. The authors generated a mouse
model with aberrant expression of GREM1 in the intestinal
epithelium, which resulted in the formation of crypt structures in
the differentiated villus compartment, similar to human HMPS.
These crypt structures proliferated and were able to acquire
additional mutations, which led to intestinal neoplasia.
Taken together, these studies showed that targeting
Wnt pathway activation alone in non-stem cells was not sufficient
to drive adenoma formation. However, additional mutations,
activation of inflammatory pathways or changes in the micro-
environment were able to increase the pool of cell of origin
to non-stem cells.
Table 1. Recent Studies
Targeted cells Cre Mutation
Tumouri-
genesis Reference




Ctnnb1ex3/þ Yes (Zhu et al,
2009)
Bmi1 Ctnnb1ex3/þ Yes (Sangiorgi and
Capecchi,
2008)




Lrig1 Apcþ / Yes (Powell et al,
2012)
Transit amplifying cells AhCre (low
oral dose)




Xbp1 Ctnnb1ex3/þ No (Schwitalla
et al, 2013)
Differentiated villus cells
(via in vitro purification
of villi cells)
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‘TOP-DOWN VS BOTTOM-UP’ DEBATE
Thus, far this review has been restricted to discussion of small
intestinal adenoma formation in mouse models, so what of the
human CRC? Obviously the cre-lox lineage tracing experiments
performed in mice cannot be done in humans, but naturally
occurring methylation or mitochondrial mutations can be used to
study the fate of stem cells in human samples. Already in 2001
Shibata and coworkers (Yatabe et al, 2001) indicated a model in
which several stem cells per crypt are present and are constantly
replaced. More recently Baker et al (2014) were able to study clonal
advantage of stem cells in humans by tracking stem cells with
unique somatic mitochondrial mutation. Here the authors confirm
the neutral drift theory in humans and show that the number of
functional stem cells in a human colonic crypt is similar to the
number in mice (5–6).
However, the histology of human CRC and early lesions in
patients with FAP had triggered a debate over the cell of origin of
CRC. This was owing to the observation that dysplastic cells are
mainly found at the luminal surface of the colon with normal crypt
cells underneath. When the lab of Bert Vogelstein microdissected
several spontaneous adenomas they found that only cells at the top
of the crypt had mutations in APC, whereas the underlying crypts
with their respective stem cells revealed no such mutations. This
led to the so called ‘top-down’ model, where tumour initiation
starts at the top of the crypt and then spreads laterally and
consequently also downwards towards the normal crypt (Shih et al,
2001).
In contrast, it has been observed in patients with familial
predispositions in the APC gene, the dysplastic cells often occupy
entire single crypts (monocryptal adenoma), which can also be
found, but rarely, in spontaneous colorectal adenomas. This
‘bottom-up’ model would predict that the stem cell at the bottom
of the crypt is the cell of tumour initiation and populates the entire
crypt (Preston et al, 2003).
UNANSWERED POINTS/CONSIDERATION
After the lessons from the induced pluripotent stem cells, it is
perhaps unsurprising that differentiated cells in the intestine could
form a tumour if given enough oncogenic events. The key question
is, could it happen in patients? From the discussion of the rapid
turnover of the intestinal epithelium, this already suggests a
hierarchy of cells that would be able to be transformed. The
likelihood of acquiring a mutation and giving rise to a phenotype
in a cell that is differentiated is unlikely due to its stop in
proliferation and short lifespan. However, a TA or a progenitor
cell, which is about to undergo a number of cell divisions, would
dilute out any remaining protein after mutation of the gene. If the
mutation conferred a selective advantage that allowed a cell and its
daughter cells to persist, then this could result in a potential cell of
origin for cancer.
However, for a cell to gain three mutations, for example, biallelic
loss of APC and a KRAS mutation would be highly unlikely.
Instead one could imagine perhaps a model where an intestinal
stem cell has a novel APCmutation which then due to drift (and an
selective advantage) makes an entire crypt APCmut/þ throughout.
One could then envisage a second mutation in a daughter cell that
persists to form a microadenoma. Further mutations such as KRAS
mutation could then drive bona fide tumour formation.
Another possibility is that certain mutations (e.g., KRAS or
BRAF) would select for mutations in an inflammatory environ-
ment via a non-APC route of tumourigenesis (e.g., traditional
serrated adenomas). These mutations could occur in long-lived
differentiated cells and give rise to adenomas owing to a changed
microenvironment.
One question still unclear is, what would be the clinical
implications of a stem cell vs a non-stem cell route for
carcinogenesis? The mouse studies would suggest that a stem cell
would need fewer mutations to form an adenoma and then would
grow more rapidly. This might suggest that these tumours may
acquire fewer mutations than ones in non-stem cells and therefore
they may be more sensitive to treatment. It is interesting to note that
the Hanahan lab identified signatures from human CRCs that could
be compared with stem cells, TA cells and more differentiated cells,
suggestive that tumours might keep the features of the cells from
which they arose (Sadanandam et al, 2013). Although only a low
number of patients were used there was some suggestion of potential
prognostic and predictive potential of these signatures.
CONCLUSION
Overall, we show that the intestinal stem cells are defined by great
plasticity. Wnt activation in the ISCs shows that they are very
potent in initiating adenoma formation. The TA cells are also able
to form adenomas, but not as potent as the stem cells. In addition,
it became evident that even differentiated cells are able to initiate
tumourigenesis but require additional events (i.e., mutations,
inflammation or changes in the microenvironment). Therefore,
we would conclude that the ISCs are the most potent cells for
transformation, but certainly not the only possible cells of origin
for colorectal cancer.
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